Home› References

Resources

References

A single, searchable library pulling together every citation used across compound research briefs — not training data, not summaries, the original sources.

Every source cited across the compound briefs, gathered here in full — 273 references across 8 compounds, in the same Vancouver format used on each page. Jump to a compound:

CBD 40 references

  1. Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol. 2023;41(7):1444–1452. Source ↗
  2. Gurgenci T, Kijanka G, Greer R, Huggett G, Good P, Moniruzzaman M, Hardy J. Exploring potential anti-inflammatory effects of medicinal cannabis. Support Care Cancer. 2023;31(11):629. Source ↗
  3. Hardy J, Greer R, Gurgenci T, et al. Medicinal cannabis for symptom control in advanced cancer: RCT of 1:1 THC and CBD. Support Care Cancer. 2025. Source ↗
  4. Aviram J, Samuelly-Leichtag G. Cannabidiol may prolong survival in patients with glioblastoma multiforme. Front Oncol. 2022;12:837513. Source ↗
  5. Sáenz-Antoñanzas A, Arriola E, Salgado J, et al. THC/CBD oral solution + TMZ and radiotherapy in newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial. Ann Oncol. 2024;35(suppl 2):S1495. Source ↗
  6. McAllister SD, Murase R, Christian RT, et al. Pathways mediating CBD effects on breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011;129(1):37–47. Source ↗
  7. Elbaz M, Nasser MW, Ravi J, et al. Modulation of the tumour microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumour mechanisms of CBD in breast cancer. Oncogenesis. 2015;4(8):e159. Source ↗
  8. Sorosina L, Singer E, Dighe P, et al. CBD inhibits RAD51 and sensitises glioblastoma to temozolomide in multiple orthotopic tumour models. Neurooncol Adv. 2022;4(1):vdac019. Source ↗
  9. Wang LP, Chagas PS, Salles ÉL, et al. CBD as prophylactic agent against glioblastoma growth: preclinical investigation. Int J Mol Sci. 2026;27(2):757. Source ↗
  10. Jeong S, Yoon S, Kim S, et al. CBD-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Lett. 2019;447:12–23. Source ↗
  11. Feng P, Zhu L, Jie J, et al. CBD inhibits invasion and metastasis in CRC by reversing EMT through Wnt/β-catenin signalling. J Cancer Res Clin Oncol. 2023;149(7):3587–3598. Source ↗
  12. Campitelli LF, Kloeppel T, Austin JR, et al. CBD rewires tumour microenvironment via inhibiting alternative activation of macrophage and synergises with anti-PD-1 in colon cancer. J Immunother Cancer. 2023;11(7):e006505. Source ↗
  13. Ramer R, Heinemann K, Merkord J, et al. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013;12(1):69–82. Source ↗
  14. Camilleri M, Kaur A, Bhatt P, et al. CBD is associated with improved survival in pancreatic cancer and modulation of bile acids and gut microbiota. Cancers (Basel). 2025. Source ↗
  15. Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2 independent of common mutations. ACS Pharmacol Transl Sci. 2025. Source ↗
  16. Luengo JMH, Reszka SJ, Stegmaier P, et al. CBD converts NF-κB into a tumour suppressor in glioblastoma with defined antioxidative properties. Neuro Oncol. 2021;23(11):1898–1911. Source ↗
  17. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. CBD as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007;6(11):2921–7. Source ↗
  18. Fan F, Liao T, Liu Y, et al. CBD attenuates lipid metabolism and induces CB1 receptor-mediated ER stress associated apoptosis in ovarian cancer cells. Sci Rep. 2025;15(1):4307. Source ↗
  19. Cannabinoids inhibit the vascular endothelial growth factor pathway. Cancer Res. 2004;64(16):5617–5623. Source ↗
  20. Cannabidiol pharmacology review: receptors, mechanisms and oncology. Front Pharmacol. 2023;14:1094020. Source ↗
  21. Cannabinoids in colorectal cancer and gut inflammation. Front Med. 2021;8:713153. Source ↗
  22. CBD modulates ER-stress responses in CRC in a KRAS-mutation-dependent manner. ResearchGate. 2024. Source ↗
  23. Shalata W, Nasrallah H, Shalata H, et al. Bioinformatic analysis predicts CBD could function as a potential inhibitor of the MAPK pathway in CRC. Int J Mol Sci. 2024;25(17):9558. Source ↗
  24. Barbagallo GM, Certo F, Scalia G, et al. Cytotoxic effects of CBD and CBG on glioblastoma stem cells may mostly involve GPR55 and TRPV1 signalling. Cancers (Basel). 2022;14(24):6070. Source ↗
  25. Martinez Naya N, Kelly J, Corna G, et al. An overview of CBD as a multifunctional drug: pharmacokinetics and cellular effects. Molecules. 2024;29(2):473. Source ↗
  26. Pyszniak M, Puzia-Szkodo J, Podgajna M, et al. Mechanisms of cell death induced by CBD against tumour cells: a review. Plants. 2025;14(4):585. Source ↗
  27. In vivo mouse LPS-challenge anti-inflammatory cytokine data (TNF-α reduction) — cited within a broader review; the specific primary study was not independently isolated and verified this session.
  28. Anti-inflammatory effects of CBD in human microglial cell line infected with HIV-1. Sci Rep. 2023.
  29. Millar SA, Stone NL, Yates AS, O'Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365. Source ↗
  30. EPIDIOLEX (cannabidiol) prescribing information. U.S. Food and Drug Administration; 2025. Source ↗
  31. Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A Phase I, Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. CNS Drugs. 2018;32(11):1053–1067. Source ↗
  32. Morales P, et al. Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism. Front Psychiatry. 2022;13:1055481. Source ↗
  33. Grayson L, Vines B, Nichol K, Szaflarski JP. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2018;9:10–11. Source ↗
  34. Morrison G, Crockett J, Blakey G, Sommerville K. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8:1009–1031.
  35. Bar-Sela G, Cohen I, Campisi-Pinto S, et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers (Basel). 2022;14(8):1957.
  36. Knaub RM, et al. Randomised single-dose crossover comparative bioavailability study of two novel oral CBD formulations vs standard CBD isolate capsule. J Cannabis Res. 2025. Source ↗
  37. Apryatin KM, Fedoseev PY, Malinovskaya EN, et al. CBD-induced crosstalk of apoptosis and macroautophagy in CRC cells involves p53 and Hsp70. Cell Death Discov. 2023;9:88. Source ↗
  38. McAllister SD, Soroceanu L, Desprez PY. CBD induces programmed cell death in breast cancer cells by coordinating cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10(7):1161–72. Source ↗
  39. Child RB, Tallon MJ. Cannabidiol (CBD) dosing: plasma pharmacokinetics and effects on accumulation in skeletal muscle, liver and adipose tissue. Nutrients. 2022;14(10):2101. Source ↗
  40. Kim J, Ahn KS. Cannabidiol Suppresses EMT in Pancreatic Cancer via Inhibition of MALAT1 lncRNA and PI3K/Akt/mTOR Signaling Pathway. IUBMB Life. 2025;77(8):e70042. Source ↗

Berberine 29 references

  1. Chen YX, Gao QY, Zou TH, Wang BM, Liu SD, Sheng JQ, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267–275. Source ↗
  2. Tan YJ, et al. Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-year follow-up of a randomized clinical trial. Cell Reports Medicine. 2025. Source ↗
  3. Xu L, Zhang Y, Xue X, Liu J, Li ZS, Yang GY, et al. A Phase I Trial of Berberine in Chinese with Ulcerative Colitis. Cancer Prev Res (Phila). 2020;13(1):117–126. Source ↗
  4. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–717. Source ↗
  5. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2024. Source ↗
  6. Tillhon M, Guamán Ortiz LM, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012;84(10):1260–1267. Source ↗
  7. Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, Jia L, Colburn NH, Young MR. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol Carcinog. 2015;54(11):1096–1109. Source ↗
  8. Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt E. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS One. 2014;9(12):e114573. Source ↗
  9. Tsang CM, Cheung YC, Lui VW, Yip YL, Zhang G, Lin VW, Cheung KC, Feng Y, Tsao SW. Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer. 2013;13:619. Source ↗
  10. Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, Jia L, Colburn NH, Young MR. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol Carcinog. 2015;54(11):1096–1109. (Same primary study as ref. 7 — this paper independently confirms both the apoptosis and NF-κB findings in the same colon-carcinogenesis model.) Source ↗
  11. Turner N, Li JY, Gosby A, To SWC, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I. Diabetes. 2008;57(5):1414–1418. Source ↗
  12. Kang YH, Wang JH, Lee JS, Hwang SJ, Lee NH, Son CG. Berberine inhibits colorectal liver metastasis via modulation of TGF-β in a cecum transplant mouse model. Eur J Med Res. 2024;29(1):552. Source ↗
  13. Wen C, Wu L, Fu L, Zhang X, et al. Berberine enhances the anti-tumor activity of tamoxifen in drug-sensitive MCF-7 and drug-resistant MCF-7/TAM cells. Mol Med Rep. 2016. Source ↗
  14. Li J, Pan Y, Kan M, Xiao X, Wang Y, Guan F, et al. Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase. Life Sci. 2014;98(1):24–30. Source ↗
  15. Kong Y, Yang H, Nie R, Zhang X, Zhang H, Nian X. Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence. Eur J Med Res. 2025;30(1):477. Source ↗
  16. Nie Q, Li M, Huang C, Yuan Y, Liang Q, Ma X, Qiu T, Li J. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med. 2024;22(1):225. Source ↗
  17. Ehteshamfar SM, et al. Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. J Cell Mol Med. 2020. Source ↗
  18. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213–217. Source ↗
  19. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients. 2021. Source ↗
  20. Hou Q, Han W, Fu X. Pharmacokinetic interaction between tacrolimus and berberine in a child with idiopathic nephrotic syndrome. Eur J Clin Pharmacol. 2013;69(10):1861–1862. Source ↗
  21. Chan E. Displacement of bilirubin from albumin by berberine. Biology of the Neonate. 1993;63(4):201–208. Source ↗
  22. Chang C, Roh YS, Du M, Kuo YC, Zhang Y, Hardy M, Gahler R, Solnier J. Differences in Metabolite Profiles of Dihydroberberine and Micellar Berberine in Caco-2 Cells and Humans—A Pilot Study. Int J Mol Sci. 2024;25(11):5625. Source ↗
  23. Solnier J, Zhang Y, Kuo YC, Du M, Roh K, Gahler R, Wood S, Chang C. Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers. Pharmaceutics. 2023;15:2567. Source ↗
  24. Ikem DC, Buzugbe SH, Okubor PC, Michael OE. Comparative In Silico ADMET Analysis of Berberine and Piperine: A Rationale for Combinatorial Therapy to Overcome P-Glycoprotein-Mediated Efflux. FUDMA Journal of Sciences. 2026;10(6):16–20.
  25. Interaction Metabolomics to Discover Synergists in Natural Product Mixtures. Source ↗
  26. Tak J, Sabarwal A, Shyanti RK, Singh RP. Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt. Mol Cell Biochem. 2019;458(1-2):49–59. Source ↗
  27. Tan CS, Wong KY, Loh HY, Yeap SK, Ho WY, Boo SY, Beh BK, Yong CY, Ho KL, Cheng WH. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One. 2013;8(10):e77969. Source ↗
  28. Shah D, Challagundla N, Dave V, Patidar A, Saha B, Nivsarkar M, et al. Berberine mediates tumor cell death by skewing tumor-associated immunosuppressive macrophages to inflammatory macrophages. Phytomedicine. 2022;99:153904. Source ↗
  29. Ruan H, Zhan YY, Hou J, Xu B, Chen B, Tian Y, Wu D, Zhao Y, Zhang Y, Chen X, et al. Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells. Oncogene. 2017;36(50):6906–6918. Source ↗

Curcumin 63 references

  1. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–6854. Source ↗
  2. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–4499. Source ↗
  3. Kroon MAGM, van Laarhoven HWM, Swart EL, van Tellingen O, Kemper EM. A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability. iScience. 2025;28(6):112575. Source ↗
  4. de Waure C, Bertola C, Baccarini G, Chiavarini M, Mancuso C. Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials. Pharmaceutics. 2023;15(4):1275. Source ↗
  5. Dharman S, G M, Shanmugasundaram K, Sampath RK. A Systematic Review and Meta-Analysis on the Efficacy of Curcumin/Turmeric for the Prevention and Amelioration of Radiotherapy/Radiochemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Asian Pac J Cancer Prev. 2021;22(6):1671–1684. Source ↗
  6. Gutsche LC, Dörfler J, Hübner J. Curcumin as a complementary treatment in oncological therapy: a systematic review. Eur J Clin Pharmacol. 2025;81:1–33. Source ↗
  7. Howells LM, Iwuji COO, Irving GRB, et al. Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. J Nutr. 2019;149(7):1133–1139. Source ↗
  8. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62(13):3868–3875. Source ↗
  9. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28(10):1461–1467. Source ↗
  10. Li S-Q, Zhu X-R, Qin B-C, Chen M-B. Curcumin in colorectal cancer: mechanistic insights, pharmacological limitations, and translational perspectives. Front Pharmacol. 2025;16:1667731. Source ↗
  11. Wang X, Tian Y, Lin H, Cao X, Zhang Z. Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1α signaling. Open Life Sci. 2023;18(1):20220618. Source ↗
  12. Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H, Chen QY. Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol Ther Oncolytics. 2016;3:16018. Source ↗
  13. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101(3):1053–1062. Source ↗
  14. Hu P, Ke C, Guo X, Ren P, Tong Y, Luo S, et al. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma. Dig Liver Dis. 2019;51(1):120–126. Source ↗
  15. Tang X, Ding H, Liang M, Chen X, Yan Y, Wan N, Chen Q, Zhang J, Cao J. Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy. Thorac Cancer. 2021;12(8):1219–1230. Source ↗
  16. Lu Y, Miao L, Wang Y, Xu Z, Zhao Y, Shen Y, Xiang G, Huang L. Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. Mol Ther. 2016;24(2):364–374. Source ↗
  17. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila). 2012;5(2):205–215. Source ↗
  18. Kim B, Kim HS, Jung EJ, Lee JY, Tsang BK, Lim JM, Song YS. Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells. Mol Carcinog. 2016;55(5):918–928. Source ↗
  19. Huang YF, Zhu DJ, Chen XW, Chen QK, Luo ZT, Liu CC, Wang GX, Zhang WJ, Liao NZ. Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway. Oncotarget. 2017;8(25):40264–40275. Source ↗
  20. Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. 2013;71(6):1521–1530. Source ↗
  21. Kanai M, Imaizumi A, Otsuka Y, et al. Dose-escalation PK of nanoparticle curcumin (Theracurmin) in healthy volunteers. Cancer Chemother Pharmacol. 2012;69(1):65–70. Source ↗
  22. Chung H, Lee Y, Lee K, et al. Comparative pharmacokinetics of Theracurmin Super vs Theracurmin in a randomised crossover study. Clin Transl Sci. 2022. Source ↗
  23. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem. 2010;58(4):2095–2099. Source ↗
  24. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardised curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011;74(4):664–669. Source ↗
  25. Antony B, Merina B, Iyer VS, et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax). Indian J Pharm Sci. 2008;70(4):445–449. Source ↗
  26. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–356. Source ↗
  27. Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. Nutr J. 2014;13:11. Source ↗
  28. Jabur L, Pandey R, Mikhael M, Niedermayer G, Gyengesi E, Mahns D, Münch G. Pharmacokinetic Analysis of the Bioavailability of AQUATURM®, a Water-Soluble Curcumin Formulation, in Comparison to a Conventional Curcumin Tablet, in Human Subjects. Pharmaceuticals (Basel). 2025;18(7):1073. Source ↗
  29. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1411–1417. Source ↗
  30. Grafeneder J, Derhaschnig U, Eskandary F, Buchtele N, Sus N, Frank J, Jilma B, Schoergenhofer C. Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK-9 Concentrations in Healthy Subjects in a Double-Blind, Randomized, Active-Controlled, Crossover Trial. Mol Nutr Food Res. 2022;66(22):e2200139. Source ↗
  31. Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008;36(8):1594–1605. Source ↗
  32. Volak LP, Hanley MJ, Masse G, et al. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol. 2013;75(2):450–462. Source ↗
  33. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a systematic review. Br J Clin Pharmacol. 2021;87(2):352–374. Source ↗
  34. Halegoua-DeMarzio D, Navarro V, Ahmad J, Avula B, Barnhart H, Barritt AS, et al. Liver Injury Associated with Turmeric—A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network (DILIN). Am J Med. 2023;136(2):200–206. Source ↗
  35. Naghsh N, Musazadeh V, Nikpayam O, Kavyani Z, Moridpour AH, Golandam F, Faghfouri AH, Ostadrahimi A. Profiling Inflammatory Biomarkers following Curcumin Supplementation: An Umbrella Meta-Analysis of Randomized Clinical Trials. Evid Based Complement Alternat Med. 2023;2023:4875636. Source ↗
  36. Farzaei MH, Zobeiri M, Parvizi F, El-Senduny FF, Marmouzi I, Coy-Barrera E, Naseri R, Nabavi SM, Rahimi R, Abdollahi M. Curcumin in Liver Diseases: A Systematic Review of the Cellular Mechanisms of Oxidative Stress and Clinical Perspective. Nutrients. 2018;10(7):855. Source ↗
  37. Chou AH, Lee HC, Liao CC, Yu HP, Liu FC. ERK/NF-kB/COX-2 Signaling Pathway Plays a Key Role in Curcumin Protection against Acetaminophen-Induced Liver Injury. Life (Basel). 2023;13(11):2150. Source ↗
  38. Fan H, Liang Y, Jiang B, Li X, Xun H, Sun J, He W, Lau HT, Ma X. Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells. Oncol Rep. 2016;35(5):2651–2656. Source ↗
  39. Fan H, Tian W, Ma X. Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase. Target Oncol. 2014;9(3):279–286. Source ↗
  40. Younesian O, Kazerouni F, Dehghan-Nayeri N, Omrani D, Rahimipour A, Shanaki M, Rezapour Kalkhoran M, Cheshmi F. Effect of Curcumin on Fatty Acid Synthase Expression and Enzyme Activity in Breast Cancer Cell Line SKBR3. Int J Cancer Manag. 2017;10(3):e8173. Source ↗
  41. Sun D, Hu D, Wang J, Li X, Peng J, Wang S. Curcumin Rewires the Tumor Metabolic Landscape: Mechanisms and Clinical Prospects. Nutrients. 2025;18(1):53. Source ↗
  42. Ding L, Li J, Song B, Xiao X, Zhang B, Qi M, Huang W, Yang L, Wang Z. Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathway. Toxicol Appl Pharmacol. 2016;304:99–109. Source ↗
  43. Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W, Lu H, Fantus IG, Jin T. Curcumin Prevents High Fat Diet Induced Insulin Resistance and Obesity via Attenuating Lipogenesis in Liver and Inflammatory Pathway in Adipocytes. PLoS One. 2012;7(1):e28784. Source ↗
  44. Dehzad MJ, Ghalandari H, Amini MR, Askarpour M. Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Complement Ther Med. 2023;75:102955. Source ↗
  45. Kocher A, Bohnert L, Schiborr C, Frank J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res. 2016;60(7):1555–1563. Source ↗
  46. Lee WJ, Chien MH, Chow JM, Chang JL, Wen YC, Lin YW, Cheng CW, Lai GM, Hsiao M, Lee LM. Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species-mediated endoplasmic reticulum stress. Sci Rep. 2015;5:10420. Source ↗
  47. Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis. 2004;25(11):2183–2189. Source ↗
  48. Zhou J, Donatelli SS, Gilvary DL, Tejera MM, Eksioglu EA, Chen X, Coppola D, Wei S, Djeu JY. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. Sci Rep. 2016;6:29521. Source ↗
  49. Luo F, Song X, Zhang Y, Chu Y. Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. Int Immunopharmacol. 2011;11(9):1234–1240. Source ↗
  50. Gbolahan OB, O'Neil BH, McRee AJ, Sanoff HK, Fallon JK, Smith PC, Ivanova A, Moore DT, Dumond J, Asher GN. A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors. Clin Transl Sci. 2022;15(5):1304–1315. Source ↗
  51. Panahi Y, Saberi-Karimian M, Valizadeh O, Behnam B, Saadat A, Jamialahmadi T, Majeed M, Sahebkar A. Effects of Curcuminoids on Systemic Inflammation and Quality of Life in Patients with Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial. Adv Exp Med Biol. 2021;1328:1–9. Source ↗
  52. Lev-Ari S, Maimon Y, Strier L, Kazanov D, Arber N. Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J Soc Integr Oncol. 2006;4(1):21–26. Source ↗
  53. Kantara C, O'Connell M, Sarkar S, Moya S, Ullrich R, Singh P. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA. Cancer Res. 2014;74(9):2487–2498. Source ↗
  54. Buhrmann C, Kraehe P, Lueders C, Shayan P, Goel A, Shakibaei M. Curcumin suppresses crosstalk between colon cancer stem cells and stromal fibroblasts in the tumor microenvironment: potential role of EMT. PLoS One. 2014;9(9):e107514. Source ↗
  55. Li Q, Ding Y, Ou Y, Li M, Jithavech P, Buranasudja V, Sritularak B, Xu Y, Rojsitthisak P, Han J. Curcuminoids Modulated the IL-6/JAK/STAT3 Signaling Pathway in LoVo and HT-29 Colorectal Cancer Cells. Curr Pharm Des. 2023;29(36):2867–2876. Source ↗
  56. Wu CS, Wu SY, Chen HC, Chu CA, Tang HH, Liu HS, Hong YR, Huang CYF, Huang GC, Su CL. Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib. J Nutr Biochem. 2019;74:108227. Source ↗
  57. Chiu TL, Su CC. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-κBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med. 2009;23(4):469–475. Source ↗
  58. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Turmeric/curcumin interaction with warfarin [safety communication]. 2018. Source ↗
  59. Stewart D, et al. Turmeric-Warfarin Interaction Resulting in Supratherapeutic INR, Bleeding, and Hospitalization [abstract]. Am J Health Syst Pharm. 2025;82(Suppl 1):S2697. Source ↗
  60. Subramaniam D, Ponnurangam S, Ramamoorthy P, Standing D, Battafarano RJ, Anant S, Sharma P. Curcumin Induces Cell Death in Esophageal Cancer Cells through Modulating Notch Signaling. PLoS One. 2012;7(2):e30590. Source ↗
  61. Aromokeye R, Si H. Combined Curcumin and Luteolin Synergistically Inhibit Colon Cancer Associated with Notch1 and TGF-β Signaling Pathways in Cultured Cells and Xenograft Mice. Cancers (Basel). 2022;14(12):3001. Source ↗
  62. Du WZ, Feng Y, Wang XF, Piao XY, Cui YQ, Chen LC, Lei XH, Sun X, Liu X, Wang HB, Li XF, Yang DB, Sun Y, Zhao ZF, Jiang T, Li YL. Curcumin suppresses malignant glioma cells growth and induces apoptosis by inhibition of SHH/GLI1 signaling pathway in vitro and vivo. CNS Neurosci Ther. 2013;19(12):926–936. Source ↗
  63. Li M, Guo T, Lin J, Huang X, Ke Q, Wu Y, Fang C, Hu C. Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway. J Ethnopharmacol. 2022;283:114689. Source ↗

Luteolin 29 references

  1. Naiki T, Naiki-Ito A, Murakami A, Kato H, Sugiyama Y, Kawai T, Kato S, Etani T, Nagai T, Shimizu N, Morikawa T, Aoki M, Gonda M, Kuang X, Nagayasu Y, Hamamoto S, Yasui T, Takahashi S. Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance. Prostate Cancer. 2025;2025:8165686. Source ↗
  2. Li C, Wang Q, Shen S, Wei X, Li G. HIF-1α/VEGF signaling-mediated epithelial-mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells. Phytother Res. 2019;33(3):798–807. Source ↗
  3. Fang B, Chen X, Wu M, Kong H, Chu G, Zhou Z, Zhang C, Chen B. Luteolin inhibits angiogenesis of the M2-like TAMs via the downregulation of hypoxia inducible factor-1α and the STAT3 signalling pathway under hypoxia. Mol Med Rep. 2018. Source ↗
  4. Yang Z, Liu H, Song Y, Gao N, Gao P, Hui Y, Li Y, Fan T. Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel-resistant esophageal squamous cell carcinoma. Int J Mol Med. 2024;54:77. Source ↗
  5. Wang L, Chen Q, Zhu L, Li Q, Zeng X, Lu L, Hu M, Wang X, Liu Z. Metabolic Disposition of Luteolin Is Mediated by the Interplay of UDP-Glucuronosyltransferases and Catechol-O-Methyltransferases in Rats. Drug Metab Dispos. 2017;45(3):306–315. Source ↗
  6. Wu G, Li J, Yue J, Zhang S, Yunusi K. Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma. Mol Med Rep. 2018;17(2):2456–2464. Source ↗
  7. Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP3A4 and CYP3A5 enzymes. Biochem Pharmacol. 2008;75(6):1426–1437. Source ↗
  8. Kaci H, Bodnárová S, Fliszár-Nyúl E, Lemli B, Pelantová H, Valentová K, Bakos É, Özvegy-Laczka C, Poór M. Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. Biomed Pharmacother. 2023;157:114078. Source ↗
  9. Cao L, Lei Q, Dong Y, Meng C, Qi Q, Li L, et al. Luteolin protects against alcoholic liver injury by restoring NRF2 stability to suppress ACSS2 nuclear accumulation. npj Sci Food. 2025;9(1):234. Source ↗
  10. Zheng Y, Chen B, Huang X, Ai C, Teng H, Chen L. Boosting luteolin bioavailability via P-glycoprotein efflux inhibition: a self-microemulsifying drug delivery systems. J Adv Res. 2026 Jan 20:S2090-1232(26)00055-X. Online ahead of print. Source ↗
  11. Fu J, Chen D, Zhao B, Zhao Z, Zhou J, Xu Y, Xin Y, Liu C, Luo L, Yin Z. Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3. PLoS ONE. 2012;7(11):e49194. Source ↗
  12. Song S, Su Z, Xu H, Niu M, Chen X, Min H, Zhang B, Sun G, Xie S, Wang H, Gao Q. Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. Cell Death Dis. 2017;8(2):e2612. Source ↗
  13. Ashokkumar P, Sudhandiran G. Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest New Drugs. 2011;29(2):273–284. Source ↗
  14. Pandurangan AK, Kumar SA, Dharmalingam P, Ganapasam S. Luteolin, a bioflavonoid inhibits azoxymethane-induced colon carcinogenesis: involvement of iNOS and COX-2. Pharmacogn Mag. 2014;10(Suppl 2):S306–310. Source ↗
  15. Kang KA, Piao MJ, Hyun YJ, Zhen AX, Cho SJ, Ahn MJ, Yi JM, Hyun JW. Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Exp Mol Med. 2019;51(4):40. Source ↗
  16. Gao G, Ge R, Li Y, Liu S. Luteolin exhibits anti-breast cancer property through up-regulating miR-203. Artif Cells Nanomed Biotechnol. 2019;47(1):3265–3271. Source ↗
  17. Shi RX, Ong CN, Shen HM. Luteolin sensitizes tumor necrosis factor-α-induced apoptosis in human tumor cells. Oncogene. 2004;23(46):7712–7721. Source ↗
  18. Wang Q, Wang H, Jia Y, et al. Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in glioblastoma. Cancer Chemother Pharmacol. 2017;79(5):1031–1041. Source ↗
  19. Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen Y, Chen H, Chu F, Zhang Y. Luteolin Promotes Cell Apoptosis by Inducing Autophagy in Hepatocellular Carcinoma. Cell Physiol Biochem. 2017;43(5):1803–1812. Source ↗
  20. Chen T, Li B, Xu Y, Meng S, Wang Y, Jiang Y. Luteolin reduces cancer-induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model. Oncol Rep. 2018;40(2):1129–1137. Source ↗
  21. Sarawek S, Derendorf H, Butterweck V. Pharmacokinetics of luteolin and metabolites in rats. Nat Prod Commun. 2008;3(12):2029–2036. Source ↗
  22. Li X, He X, Chen S, Le Y, Bryant MS, Guo L, Witt KL, Mei N. The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells. Toxicol Lett. 2021;344:58–68. Source ↗
  23. Choi BM, Lim DW, Lee JA, Gao SS, Kwon DY, Kim BR. Luteolin suppresses cisplatin-induced apoptosis in auditory cells: possible mediation through induction of heme oxygenase-1 expression. J Med Food. 2008;11(2):230–236. Source ↗
  24. Zhu RZ, Li BS, Gao SS, Seo JH, Choi BM. Luteolin inhibits H2O2-induced cellular senescence via modulation of SIRT1 and p53. Korean J Physiol Pharmacol. 2021;25(4):297–305. Source ↗
  25. Zechner J, Britza SM, Farrington R, Byard RW, Musgrave IF. Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis. Life Sci. 2022;291:119975. Source ↗
  26. Terzo S, Amato A, Magán-Fernández A, Castellino G, Calvi P, Chianetta R, Giglio RV, Patti AM, Nikolic D, Firenze A, Mulè F, Ciaccio M, Rizzo M. A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2023;15(2):462. Source ↗
  27. Castellino G, Nikolic D, Magán-Fernández A, Malfa GA, Chianetta R, Patti AM, Amato A, Montalto G, Toth PP, Banach M, Cicero AFG, Rizzo M. Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients. 2019;11(11):2580. Source ↗
  28. Zhou P, Li LP, Luo SQ, Jiang HD, Zeng S. Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. J Agric Food Chem. 2008;56(1):296–300. Source ↗
  29. Sá C, Oliveira AR, Machado C, Azevedo M, Pereira-Wilson C. Effects on Liver Lipid Metabolism of the Naturally Occurring Dietary Flavone Luteolin-7-glucoside. Evid Based Complement Alternat Med. 2015;2015:647832. Source ↗

Black Seed Oil 29 references

  1. Park JE, Kim DH, Ha E, Choi SM, Choi JS, Chun KS, Joo SH. Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3. Chem Biol Interact. 2019;312:108799. Source ↗
  2. Zhu WQ, Wang J, Guo XF, Liu Z, Dong WG. Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro. World J Gastroenterol. 2016;22(16):4149–4159. Source ↗
  3. Al-Rawashde FA, Al-wajeeh AS, Nazari Vishkaei M, Saad HKM, Johan MF, Wan Taib WR, Ismail I, Al-Jamal HAN. Thymoquinone inhibits JAK/STAT and PI3K/Akt/mTOR signaling pathways in MV4-11 and K562 myeloid leukemia cells. Pharmaceuticals (Basel). 2022;15(9):1123. Source ↗
  4. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-κB activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res. 2008;6(6):1059–1070. Source ↗
  5. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB, Liu M. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 2008;7(7):1789–1796. Source ↗
  6. Woo CC, Hsu A, Kumar AP, Sethi G, Tan KHB. Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS. PLoS One. 2013;8(10):e75356. Source ↗
  7. Behnamfar N, Parsa Yekta Z, Mojab F, Kazem Naeini SM. The effect of nigella sativa oil on the prevention of phlebitis induced by chemotherapy: a clinical trial. Biomedicine (Taipei). 2019;9(3):20. Source ↗
  8. Hussain SA, Mohammed Ameen HA, Mohammed MO, Ahmed KM, Hama-Gareb Ali R, Safar BM, Saeed KA. Nigella sativa oil mouth rinse improves chemotherapy-induced oral mucositis in patients with acute myeloid leukemia. Biomed Res Int. 2019;2019:3619357. Source ↗
  9. Nabil G, Zahran FM, ElMeshad A, Fawzy A, Ghalwash D, Elsaadany B. Evaluation of thymoquinone cancer chemo-preventive effect on oral leukoplakia: a randomized clinical trial. Explor Med. 2025;6:1001290. doi:10.37349/emed.2025.1001290. Trial registration: NCT03208790. Source ↗
  10. Khonche A, Huseini HF, Gholamian M, Mohtashami R, Nabati F, Kianbakht S. Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: a randomized, double-blind and placebo-controlled clinical trial. J Ethnopharmacol. 2019;234:106–111. Source ↗
  11. Dong J, Zhang X, Wang S, Xu C, Gao M, Liu S, Li X, Cheng N, Han Y, Wang X, Han Y. Thymoquinone prevents dopaminergic neurodegeneration by attenuating oxidative stress via the Nrf2/ARE pathway. Front Pharmacol. 2021;11:615598. Source ↗
  12. Alkharfy KM, Ahmad A, Khan RMA, Al-Shagha WM. Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur J Drug Metab Pharmacokinet. 2015;40(3):319–323. Source ↗
  13. Albassam AA, Ahad A, Alsultan A, Al-Jenoobi FI. Inhibition of cytochrome P450 enzymes by thymoquinone in human liver microsomes. Saudi Pharm J. 2018;26(5):673–677. Source ↗
  14. Wang Z, Wang X, Wang Z, Lv X, Yin H, Li W, Li W, Jiang L, Liu Y. Potential herb-drug interaction risk of thymoquinone and phenytoin. Chem Biol Interact. 2022;353:109801. Source ↗
  15. Sener K, Cakir A, Yesiloglu O, Altug E, Guven R, Korkut S. Rhabdomyolysis and acute kidney injury after consumption of black seed oil. Toxicon. 2024;245:107787. Source ↗
  16. Zhang Y, Liu X, Dang W, Liu L. Thymoquinone inhibits lung cancer stem cell properties via triggering YAP degradation. Carcinogenesis. 2023;44(5):426–435. Source ↗
  17. Khan MA, Tania M, Wei C, Mei Z, Fu S, Cheng J, Xu J, Fu J. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition. Oncotarget. 2015;6(23):19580–19591. Source ↗
  18. Shanmugam MK, Ahn KS, Hsu A, Woo CC, Yuan Y, Tan KHB, Chinnathambi A, Alahmadi TA, Alharbi SA, Koh APF, Arfuso F, Huang RYJ, Lim LHK, Sethi G, Kumar AP. Thymoquinone inhibits bone metastasis of breast cancer cells through abrogation of the CXCR4 signaling axis. Front Pharmacol. 2018;9:1294. Source ↗
  19. Zhang L, Bai Y, Yang Y. Thymoquinone chemosensitizes colon cancer cells through inhibition of NF-κB. Oncol Lett. 2016;12(4):2840–2845. Source ↗
  20. Alshaibi HF, Aldarmahi NA, Alkhattabi NA, Alsufiani HM, Tarbiah NI. Studying the anticancer effects of thymoquinone on breast cancer cells through natural killer cell activity. Biomed Res Int. 2022;2022:9218640. Source ↗
  21. Hadi V, Kheirouri S, Alizadeh M, Khabbazi A, Hosseini H. Effects of Nigella sativa oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Avicenna J Phytomed. 2016;6(1):34–43. Source ↗
  22. Ahmad A, Alkharfy KM, Jan BL, Ahad A, Ansari MA, Al-Jenoobi FI, Raish M. Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis. Exp Lung Res. 2020;46(3-4):53–63. Source ↗
  23. Alam MF, Khan G, Safhi MM, Alshahrani S, Siddiqui R, Moni SS, Anwer T. Thymoquinone ameliorates doxorubicin-induced cardiotoxicity in Swiss albino mice by modulating oxidative damage and cellular inflammation. Cardiol Res Pract. 2018;2018:1483041. Source ↗
  24. Mohan ME, Thomas JV, Mohan MC, Das SS, Prabhakaran P, Pulikkaparambil Sasidharan BC. A proprietary black cumin oil extract (Nigella sativa) (BlaQmax®) modulates stress-sleep-immunity axis safely: randomized double-blind placebo-controlled study. Front Nutr. 2023;10:1152680. Source ↗
  25. Thomas JV, Mohan ME, Prabhakaran P, Das SS, Maliakel B, Krishnakumar IM. A phase I clinical trial to evaluate the safety of thymoquinone-rich black cumin oil (BlaQmax®) on healthy subjects: randomized, double-blinded, placebo-controlled prospective study. Toxicol Rep. 2022;9:999–1007. Source ↗
  26. National Institute of Diabetes and Digestive and Kidney Diseases. Black Cumin Seed. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institutes of Health; 2012– [updated 2023 Apr 27]. Source ↗
  27. Ahmad A, Alqahtani S, Jan BL, Raish M, Rabba AK, Alkharfy KM. Gender effect on the pharmacokinetics of thymoquinone: preclinical investigation and in silico modeling in male and female rats. Saudi Pharm J. 2020;28(4):403–408. Source ↗
  28. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–661. Source ↗
  29. Tekbaş A, Bremer-Streck S, Wissenbach DK, Peters FT, von Lilienfeld-Toal M, Soonawalla Z, Rauchfuß F, Settmacher U, Dahmen U. Gas chromatography–mass spectrometry detection of thymoquinone in oil and serum for clinical pharmacokinetic studies. Int J Mol Sci. 2023;24(22):16431. Source ↗

EGCG 34 references

  1. Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, Weinstein IB. (−)-Epigallocatechin gallate and Polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res. 2005;11(7):2735–2746. Source ↗
  2. Chow HH, Hakim IA, Vining DR, et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res. 2005;11(12):4627–4633. Source ↗
  3. Jung YD, Kim MS, Shin BA, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer. 2001;84(6):844–850. Source ↗
  4. Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013;119(2):363–370. Source ↗
  5. Oh S, Gwak J, Park S, Yang CS. Green tea polyphenol EGCG suppresses Wnt/β-catenin signaling by promoting GSK-3β- and PP2A-independent β-catenin phosphorylation/degradation. BioFactors. 2014;40(6):586–595. Source ↗
  6. Chen Y, Wang XQ, Zhang Q, et al. (−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway. Nutrients. 2017;9(6):572. Source ↗
  7. Kwon OS, Jung JH, Shin EA, Park JE, Park WY, Kim SH. Epigallocatechin-3-Gallate Induces Apoptosis as a TRAIL Sensitizer via Activation of Caspase 8 and Death Receptor 5 in Human Colon Cancer Cells. Biomedicines. 2020;8(4):84. Source ↗
  8. Shen K, Feng X, Su R, Xie H, Zhou L, Zheng S. Epigallocatechin 3-Gallate Ameliorates Bile Duct Ligation Induced Liver Injury in Mice by Modulation of Mitochondrial Oxidative Stress and Inflammation. PLoS ONE. 2015;10(5):e0126278. Source ↗
  9. Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer. PLoS ONE. 2012;7(2):e31067. Source ↗
  10. Hu J, Webster D, Cao J, Shao A. The safety of green tea and green tea extract consumption in adults — results of a systematic review. Regul Toxicol Pharmacol. 2018;95:412–433. Source ↗
  11. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors. Blood. 2009;113(23):5927–5937. Companion commentary: Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green tea for you? Blood. 2009;113(23):5695–5696. Source ↗
  12. Yuan JH, Li YQ, Yang XY. Protective Effects of Epigallocatechin Gallate on Colon Preneoplastic Lesions Induced by 2-Amino-3-Methylimidazo[4,5-f]Quinoline in Mice. Mol Med. 2008;14(9-10):590–598. Source ↗
  13. Bannerman B, Xu L, Jones M, Tsu C, Yu J, Hales P, Monbaliu J, Fleming P, Dick L, Manfredi M, Claiborne C, Bolen J, Kupperman E, Berger A. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol. 2011;68(5):1145–1154. Source ↗
  14. Shanafelt TD, Call TG, Zent CS, et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009;27(23):3808–3814. Source ↗
  15. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM, Park OJ. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett. 2007;247(1):115–121. Source ↗
  16. Park SY, Lee YK, Kim YM, et al. Control of AMP-activated protein kinase, Akt, and mTOR in EGCG-treated HT-29 colon cancer cells. Food Sci Biotechnol. 2013;22:147–151. Source ↗
  17. Khiewkamrop P, Surangkul D, Srikummool M, Richert L, Pekthong D, Parhira S, Somran J, Srisawang P. Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells. FEBS Open Bio. 2022;12(5):937–958. Source ↗
  18. Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, Pineau B, Weber P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res. 2003;31(2):88–101. Source ↗
  19. Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, Lambert G, Mohr S, Yang CS. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev. 2002;11(10):1025–1032. Source ↗
  20. Md Nesran ZN, Shafie NH, Ishak AH, Mohd Esa N, Ismail A, Md Tohid SF. Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2α/ATF4 and IRE1α. Biomed Res Int. 2019;2019:3480569. Source ↗
  21. Li T, Zhao N, Lu J, Zhu Q, Liu X, Hao F, Jiao X. Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways. Bioengineered. 2019;10(1):282–291. Source ↗
  22. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69(20):7986–7993. Source ↗
  23. Qing G, Li B, Vu A, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012;22(5):631–644. Source ↗
  24. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study. Cancer Res. 2006;66(2):1234–1240. Source ↗
  25. Kumar NB, Pow-Sang J, Egan KM, et al. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015;8(10):879–887. Source ↗
  26. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP. A novel prodrug of the green tea polyphenol (−)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res. 2007;67(9):4303–4310. Source ↗
  27. Lee SC, Chan WK, Lee TW, Lam WH, Wang X, Chan TH, Wong YC. Effect of a prodrug of the green tea polyphenol (−)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Nutr Cancer. 2008;60(4):483–491. Source ↗
  28. Younes M, Aggett P, Aguilar F, et al. Scientific opinion on the safety of green tea catechins. EFSA J. 2018;16(4):e05239. Source ↗
  29. Oketch-Rabah HA, Roe AL, Rider CV, et al. United States Pharmacopeia (USP) Comprehensive Review of the Hepatotoxicity of Green Tea Extracts. Toxicol Rep. 2020;7:386–402. Source ↗
  30. Health Canada. Monograph: Green Tea Extract. Natural Health Products Ingredients Database. 2017. Source ↗
  31. Hayashi A, Terasaka S, Nukada Y, Kameyama A, Yamane M, Shioi R, et al. 4″-Sulfation Is the Major Metabolic Pathway of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites, Enzymatic Analysis, and Pharmacokinetic Profiling. J Agric Food Chem. 2022;70(27):8264–8273. Source ↗
  32. Ge J, Tan BX, Chen Y, et al. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med (Berl). 2011;89(6):595–602. Source ↗
  33. Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC. Population nutrikinetics of green tea extract. PLoS ONE. 2018;13(2):e0193074. Source ↗
  34. Van TTT, Chang HS, Wu HC, Lu CK, Huang HC, Korinek M, Hsiao HH, Yen CH. The SAR analysis of dietary polyphenols and their antagonistic effects on bortezomib at physiological concentrations. Front Pharmacol. 2024;15:1403424. Source ↗

CBG 18 references

  1. Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis. 2014;35(12):2787–2797. Source ↗
  2. Park JH, Hwang YN, Na HH, Kim DY, Lee HJ, Kwon TH, Park JS, Kim KC. Cannabigerol treatment shows antiproliferative activity and causes apoptosis of human colorectal cancer cells. J Pharmacopuncture. 2024;27(4):332–339. Source ↗
  3. Lah TT, Novak M, Pena Almidon MA, Marinelli O, Žvar Baškovič B, Majc B, Mlinar M, Bošnjak R, Breznik B, Zomer R, Nabissi M. Cannabigerol is a potential therapeutic agent in a novel combined therapy for glioblastoma. Cells. 2021;10(2):340. Source ↗
  4. Zagzoog A, Halter K, Ha N, Jones AM, Andres R, Kim A, Michel D, Alcorn J, Laprairie RB. Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL/6Crl mouse. Front Pharmacol. 2025;16:1672098. Source ↗
  5. Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep. 2024;14:16163. Source ↗
  6. Story G, Lee J, Cohen G, Rani A, Doherty J, Sela DA. Impact of dietary fat and oral delivery system on cannabigerol pharmacokinetics in adults. Cannabis Cannabinoid Res. 2024;9(6):1543–1555. doi:10.1089/can.2023.0174. Source ↗
  7. Wolinsky D, Srungaram D, Zhang A, Moore CF, Pierce-Messick ZJ, Zamarripa CA, Spindle TR, Strickland JC, Sempio C, Klawitter J, Campos Palomino J, Christians U, Feldner MT, Vandrey R, Bonn-Miller MO, Weerts EM, Bergeria CL. Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol (CBG) in healthy adults. J Pharmacol Exp Ther. 2026;104984. doi:10.1016/j.jpet.2026.104984. Epub ahead of print. Source ↗
  8. Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. Survey of patients employing cannabigerol-predominant cannabis preparations: perceived medical effects, adverse events, and withdrawal symptoms. Cannabis Cannabinoid Res. 2022;7(6):706–716. Source ↗
  9. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204–212. Source ↗
  10. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306–1316. Source ↗
  11. Anderson BD, Sepulveda DE, Nachnani R, Cortez-Resendiz A, Coates MD, Beckett A, Bisanz JE, Kellogg JJ, Raup-Konsavage WM. High cannabigerol hemp extract moderates colitis and modulates the microbiome in an inflammatory bowel disease model. J Pharmacol Exp Ther. 2024;390(3):331–341. Source ↗
  12. Ryšánek P, Jelínek P, Housar H, Kozlík P, Křížek T, Nováková A, Sklenárová M, Paulusová V, Merdita S, Arora M, Symkanych O, Šteigerová M, Zmeškalová E, Slanař O, Šoóš M, Šíma M. Effect of quantitative structural properties and drug formulation in four cannabinoids (cannabidiol, cannabigerol, cannabichromene, and cannabinol) on their lymphatic transport after enteral administration in rats. Mol Pharm. 2025;22(8):4544–4555. Source ↗
  13. Serrano-Rodríguez JM, Miraz R, Saitua A, Díez de Castro E, Ledesma-Escobar C, Ferreiro-Vera C, Priego-Capote F, Sánchez de Medina V, Sánchez de Medina A. Metabolism, pharmacokinetics, and bioavailability of cannabigerol in horses following intravenous and oral administration with micellar and oil formulations. Front Vet Sci. 2025;12:1688214. Source ↗
  14. Dada S, Ellis SLS, Wood C, Nohara LL, Dreier C, Garcia NH, Saranchova I, Munro L, Pfeifer CG, Eyford BA, Kari S, Garrovillas E, Caspani G, Al Haddad E, Gray PW, Morova T, Lack NA, Andersen RJ, Tjoelker L, Jefferies WA. Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours. Front Immunol. 2023;13:982082. doi:10.3389/fimmu.2022.982082. Source ↗
  15. Lamtha T, Tabtimmai L, Songtawee N, Tansakul N, Choowongkomon K. Structural analysis of cannabinoids against EGFR-TK leads a novel target against EGFR-driven cell lines. Curr Res Pharmacol Drug Discov. 2022;3:100132. Source ↗
  16. Zeppa L, Aguzzi C, Morelli MB, Marinelli O, Giangrossi M, Luongo M, Amantini C, Santoni G, Nabissi M. Cannabigerol induces autophagic cell death by inhibiting EGFR-RAS pathways in human pancreatic ductal adenocarcinoma cell lines. Int J Mol Sci. 2024;25(4):2001. Source ↗
  17. Mahmoud AM, Kostrzewa M, Marolda V, Cerasuolo M, Maccarinelli F, Coltrini D, Rezzola S, Giacomini A, Mollica MP, Motta A, Paris D, Zorzano A, Di Marzo V, Ronca R, Ligresti A. Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer. Pharmacol Res. 2023;189:106683. doi:10.1016/j.phrs.2023.106683. CBD is this paper's primary subject; CBG appears as a secondary comparator, and only the outcome-level CBG finding is used on this page. Source ↗
  18. Aguzzi C, Zeppa L, Morelli MB, Marinelli O, Giangrossi M, Amantini C, Santoni G, Sazzad H, Nabissi M. Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma. BioFactors. 2024;50(6):1208–1219. doi:10.1002/biof.2078. One co-author is affiliated with a cannabinoid company (Entourage Biosciences Inc.); noted here for research-context transparency, not as a reason to discount the findings. Source ↗

Boswellia 31 references

  1. Kirste S, Treier M, Wehrle SJ, Becker G, Abdel-Tawab M, Gerbeth K, Hug MJ, Lubrich B, Grosu AL, Momm F. Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer. 2011;117(16):3788–3795. Source ↗
  2. Di Pierro F, Simonetti G, Petruzzi A, Bertuccioli A, Botta L, Bruzzone MG, Cuccarini V, Fariselli L, Lamperti E. A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience. J Neurosurg Sci. 2019;63(3):286–291. Source ↗
  3. Bonilla Valente IV, Garcia D, Abbott A, Spruill L, Siegel J, Forcucci J, Hanna G, Mukherjee R, Hamann M, Hilliard E, Lockett M, Cole DJ, Klauber-DeMore N. The anti-proliferative effects of a frankincense extract in a window of opportunity phase Ia clinical trial for patients with breast cancer. Breast Cancer Res Treat. 2024;204(3):521–530. Source ↗
  4. Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer. 2012;130(9):2176–2184. Source ↗
  5. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M. Acetyl-11-keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009;69(14):5893–5900. Source ↗
  6. RETRACTED — not used as supporting evidence on this page. Park B, Prasad S, Yadav V, Sung B, Aggarwal BB. Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. PLoS One. 2011;6(10):e26943. Retracted: PLoS One. 2022;17(9):e0275582, for non-compliance with the journal's Animal Research Policy (tumour-size monitoring/IACUC protocol concerns) — not a finding of fabricated data. Source ↗ Retraction notice ↗
  7. Khan MA, Singh M, Khan MS, Najmi AK, Ahmad S. Caspase mediated synergistic effect of Boswellia serrata extract in combination with doxorubicin against human hepatocellular carcinoma. Biomed Res Int. 2014;2014:294143. Source ↗
  8. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. Acetyl-11-keto-β-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-κB and NF-κB-regulated gene expression. J Immunol. 2006;176(5):3127–3140. Source ↗
  9. Park B, Sung B, Yadav VR, Cho SG, Liu M, Aggarwal BB. Acetyl-11-keto-β-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. Int J Cancer. 2011;129(1):23–33. Source ↗
  10. Takahashi M, Sung B, Shen Y, Hur K, Link A, Boland CR, Aggarwal BB, Goel A. Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis. 2012;33(12):2441–2449. Source ↗
  11. Glaser T, Winter S, Groscurth P, Safayhi H, Sailer ER, Ammon HPT, Schabet M, Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer. 1999;80(5-6):756–765. Source ↗
  12. Syrovets T, Büchele B, Gedig E, Slupsky JR, Simmet T. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα. Mol Pharmacol. 2000;58(1):71–81. Source ↗
  13. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011;50(6):349–369. Source ↗
  14. Sterk V, Büchele B, Simmet T. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med. 2004;70(12):1155–1160. Source ↗
  15. Hüsch J, Bohnet J, Fricker G, Skarke C, Artaria C, Appendino G, Schubert-Zsilavecz M, Abdel-Tawab M. Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. Fitoterapia. 2013;84:89–98. Source ↗
  16. Sengupta K, Kolla JN, Krishnaraju AV, Yalamanchili N, Rao CV, Golakoti T, Raychaudhuri S, Raychaudhuri SP. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011;354(1-2):189–197. Source ↗
  17. Karlapudi V, Sunkara KB, Konda PR, Sarma KVS, Rokkam MP. Efficacy and Safety of Aflapin®, a Novel Boswellia Serrata Extract, in the Treatment of Osteoarthritis of the Knee: A Short-Term 30-Day Randomized, Double-Blind, Placebo-Controlled Clinical Study. J Am Nutr Assoc. 2023;42(2):159–168.
  18. Sengupta K, Krishnaraju AV, Vishal AA, Mishra A, Golakoti T, Sarma KVS, Raychaudhuri SK, Raychaudhuri SP. Comparative efficacy and tolerability of 5-Loxin® and Aflapin® against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7(6):366–377.
  19. Franceschi F, Togni S, Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Eggenhoffner R, Giacomelli L. A novel lecithin based delivery form of Boswellic acids (Casperome®) for the management of osteo-muscular pain: a registry study in young rugby players. Eur Rev Med Pharmacol Sci. 2016;20(19):4156–4161. Source ↗
  20. Roe AL, Wilcox R, Price JM, Li L, Dai H, Freeman KM, Friley WW, Herman AG, Black CB, Brouwer KR, Jackson JP. An Evaluation of Potential Inhibition of CYP3A4/5 and CYP2C9 Enzymatic Activity by Boswellia serrata Extract. Appl In Vitro Toxicol. 2019;5(1):34–46.
  21. Davis B, Sengupta K, Alluri VK, Golakoti T. Plasma Concentrations of Boswellic Acids in Fasting Healthy Humans Supplemented with a Water-Soluble Boswellia Extract (78% AKBA) vs. Reference Boswellia Extract (30% AKBA). Curr Dev Nutr. 2019;3(Suppl 1). Conference-abstract-level source, used only for the water-soluble Formulation comparator.
  22. Krishnaraju AV, Sundararaju D, Vamsikrishna U, Suryachandra R, Machiraju G, Sengupta K, Trimurtulu G. Safety and toxicological evaluation of Aflapin®: A novel Boswellia-derived anti-inflammatory product. Toxicol Mech Methods. 2010;20(9):556–563. Source ↗
  23. European Medicines Agency. Orphan designation EU/3/02/117 for Boswellia serrata resin extract for the treatment of peritumoral oedema derived from brain tumours. Granted to Pharmasan GmbH, 21 October 2002 (withdrawn 2006 at sponsor's request). Source ↗
  24. Riva A, Giacomelli L, Togni S, Franceschi F, Eggenhoffner R, Zuccarini MC, Belcaro G. Oral administration of a lecithin-based delivery form of boswellic acids (Casperome®) for the prevention of symptoms of irritable bowel syndrome: a randomized clinical study. Minerva Gastroenterol Dietol. 2019;65(1):30–35.
  25. Belcaro G, Gizzi G, Pellegrini L, Corsi M, Dugall M, Cacchio M, Feragalli B, Togni S, Riva A, Eggenhoffner R, Giacomelli L. Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017;21(9):2249–2254.
  26. Madisch A, Miehlke S, Eichele O, et al. Boswellia serrata extract for the treatment of collagenous colitis: a double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. 2007;22(12):1445–1451.
  27. Ammon HP. Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine. 2010;17(11):862–867. Source ↗
  28. Riva A, Morazzoni P, Artaria C, Allegrini P, Meins J, Savio D, Appendino G, Schubert-Zsilavecz M, Abdel-Tawab M. A single-dose, randomized, cross-over, two-way, open-label study for comparing the absorption of boswellic acids and its lecithin formulation. Phytomedicine. 2016;23(12):1375–1382.
  29. Schmiech M, Abdel-Kahaar E, Ulrich J, Pfeiffer M, Duweb A, Zolk O, Syrovets T, Simmet T. Single-dose comparative pharmacokinetic/pharmacodynamic study of a micellar formulation versus a native Boswellia serrata dry extract in healthy volunteers. Phytomedicine. 2024;132:155863. Source ↗
  30. Feragalli B, Ippolito E, Dugall M, Cesarone MR, Cornelli U, Corsi M, Belcaro G. Effectiveness of a novel boswellic acids delivery form (Casperome®) in the management of grade II ankle sprains due to sport trauma — a registry study. Eur Rev Med Pharmacol Sci. 2017;21(20):4726–4732.
  31. Kulkarni PD, et al. Pharmacokinetics of Solid Lipid Boswellia Serrata Particles in Healthy Subjects. Drug Metab Pers Ther. 2021;36(3):215–221. Source ↗